Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study

BACKGROUND: Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. Major CFS symptom relief during cancer chemotherapy in a patient with synchronous CFS and lymphoma spurred a pilot study of B-lymphocyte depletion using the anti-CD20 antibody Rituximab, which demonstrated significant clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fluge, Øystein, Bruland, Ove, Risa, Kristin, Storstein, Anette, Kristoffersen, Einar K., Sapkota, Dipak, Næss, Halvor, Dahl, Olav, Nyland, Harald, Mella, Olav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198463/
https://www.ncbi.nlm.nih.gov/pubmed/22039471
http://dx.doi.org/10.1371/journal.pone.0026358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198463/
https://www.ncbi.nlm.nih.gov/pubmed/22039471
http://dx.doi.org/10.1371/journal.pone.0026358

Ejemplares similares